6 results about "Liver enzyme" patented technology

Provided herein are anti-Activin E antibodies having specific complementarity determining regions (CDRs) for the heavy and light chains, heavy and light chains, antigen binding fragments thereof, polynucleotides that encode the same, vectors, and host cells, and methods for treating a metabolic disorder, type 2 diabetes, obesity, an elevated triglyceride level, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, an elevated liver enzyme, nonalcoholic steatohepatitis (NASH), a cardiovascular disease, cardiomyopathy, high blood pressure, and / or heart failure with the anti-Activin E antibodies disclosed herein.

This invention relates to the field of livestock and poultry breeding and food safety testing technology, and in particular to a method for assessing copper exposure hepatotoxicity based on the endoplasmic reticulum stress-endoplasmic reticulum autophagy axis and its application. This method obtains liver tissue samples or in vitro cultured hepatocyte samples from copper-exposed subjects, and jointly detects the expression levels of key markers of the endoplasmic reticulum stress pathway and characteristic markers of the endoplasmic reticulum autophagy pathway. Combined with two-way pharmacological validation, a grading assessment standard for copper exposure hepatotoxicity is established. This invention overcomes the shortcomings of traditional liver enzyme indicators, such as low sensitivity and strong lag, and has the advantages of early warning, high specificity, and reliable results. It can be widely applied to scenarios such as determining the copper safety threshold in livestock and poultry feed, early screening for copper exposure hepatotoxicity, assessment of copper pollution ecological risks, and screening of copper toxicity protectants, providing technical support for ensuring animal health and the safety of animal-derived food.

This article describes methods, compositions, and systems derived from uncultured microorganisms that can be used to supplement liver enzyme deficiencies.

Provided herein are anti-Activin E antibodies having specific complementarity determining regions (CDRs) for the heavy and light chains, heavy and light chains, antigen binding fragments thereof, polynucleotides that encode the same, vectors, and host cells, and methods for treating a metabolic disorder, type 2 diabetes, obesity, an elevated triglyceride level, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, an elevated liver enzyme, nonalcoholic steatohepatitis (NASH), a cardiovascular disease, cardiomyopathy, high blood pressure, and / or heart failure with the anti-Activin E antibodies disclosed herein.

A method for identifying a cause of elevated liver enzymes includes receiving new patient data, receiving a machine-learning based diagnostic model and a knowledge based diagnostic model, determining whether the machine-learning based diagnostic model indicates a cause of elevated liver enzymes for the new patient data, and in a case where the machine-learning based diagnostic model indicates the cause of elevated liver enzymes for the new patient data, assessing the cause of elevated liver enzymes using the knowledge based diagnostic model.

The application belongs to the technical field of biological medicine, and particularly relates to POFUT1 The application discloses an application of a gene function inhibitor in preparation of a drug for treating cholestatic liver disease. POFUT1 It is found for the first time that inhibition of the function of the gene can significantly reduce the degree of liver lesion of cholestatic liver disease. POFUT1 The deletion of the gene can significantly reduce serum liver enzyme, bile acid and bilirubin levels, reduce liver inflammatory cell infiltration and collagen deposition. Further verification by AAV8-mediated RNA interference technology shows that targeted silencing of the gene in liver cells can effectively alleviate liver injury and liver fibrosis. POFUT1 The application provides a novel treatment target and strategy for cholestatic liver disease, and has a wide clinical application prospect.